Servier and Guangdong Maijinjia Biotechnologies (MJJ Biotech) and Ranger Biotechnologies announced a collaboration and exclusive license option agreement to develop a novel therapy for treating rare neurodegenerative diseases.
MJJ Biotech is the owner of a proprietary technology platform, Blockmir, acquired from Ranger Biotechnologies, which uses short highly modified oligonucleotides to upregulate protein expression.
“This collaboration is a unique opportunity to partner with an experienced and recognized player in the field of antisense oligonucleotide (ASOs) Blockmirs to help us design and optimize ASOs by gaining access to models, technology, and experience that complements our own capabilities in order to provide patients suffering from neurodegenerative diseases with innovative therapeutic solutions”, stated Johannes Krupp, Research Program Director Neurology, Servier.
Servier has the option to license, develop and commercialize novel therapeutic medicines based on this technology.
Servier has been involved in neuroscience for several decades and focuses its research on neurodegenerative diseases. Servier is particularly interested in targeted movement disorders, such as Parkinson’s disease, amyotrophic lateral sclerosis and spinocerebellar ataxias, many of which are characterized by the abnormal accumulation of certain proteins.